ArticleProstate international2018

Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 study.

Darren M C Poon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.